# US 2025/0085280 A1 · Methods for Detecting Antibody Self-Association

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0085280 A1
- Document ID: US20250085280A1
- Status: Published application
- Kind: A1
- Application number: 18/730,373
- Filed: 2023-01-23
- Published: 2025-03-13
- Earliest claimed: 2022-01-24
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Yuqing Shen; Emma Montserrat Pelegri-O'Day
- Web page: https://patentgrep.com/patent/US20250085280A1

## CPC

- G01N 33/54346: {Nanoparticles}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 33/54386: {Analytical elements}
- G01N 33/553: Metal or metal coated
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- G01N 33/686: {Anti-idiotype}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosure provides for methods and systems for detecting antibody protein product self-association comprising inducing co-agglutination of nanoparticles and solid supports to capture the nanoparticles, each coated with a ligand specific for immunoglobulins, and utilizing a fluidic device to detect co-agglutination and antibody protein product self-association.

## Claims

### Claim 1

A method of detecting antibody protein product association comprising
a) contacting a sample comprising an antibody protein product with nanoparticles coated with a ligand for an antibody protein product, wherein the contacting occurs in a fluidic device under conditions that allow antibody protein products to self-associate, thereby forming clusters of nanoparticles,
b) contacting the clusters of nanoparticles with a solid support, wherein the solid support is coated with a ligand for the antibody protein product of (a), and
c) detecting a change in optical signal of the nanoparticles and/or the solid support, wherein a change in optical signal indicates antibody protein product association.

### Claim 2 (depends on 1)

The method of claim 1 wherein the sample comprises conditioned media.

### Claim 3

The method of any of the preceding claims, wherein the antibody protein product comprises or consists of a large peptide, antibody, antibody fragment, antibody fusion peptide or antigen-binding fragment thereof.

### Claim 4

The method of any of the preceding claims, wherein the nanoparticles have a mean diameter ranging in size between about 10 nm to about 50 nm.

### Claim 5

The method of any of the preceding claims, wherein the nanoparticles have a mean diameter of about 20 nm or about 30 nm.

### Claim 6

The method of any of the preceding claims, wherein the nanoparticles are coated with an antibody or fragment thereof that specifically binds human Fc protein, protein A or protein G, or a combination thereof.

### Claim 7

The method of any of the preceding claims, wherein the solid support is a bead, resin or agarose.

### Claim 8

The method of any of the preceding claims, wherein the nanoparticle comprises or consists of a metal or a polymer.

### Claim 9 (depends on 8)

The method of claim 8, wherein the nanoparticle comprises or consists of gold.

### Claim 10

The method of any of the preceding claims, wherein the solid support is coated with an antibody or fragment thereof that specifically binds human Fc protein, protein A or protein G, or a combination thereof.

### Claim 11

The method of any of the preceding claims, wherein the solid support is a bead having a mean diameter at least 2×, 5×, 10×, 50×, 100×, 500×, or 1000× that of the nanoparticle.

### Claim 12

The method of any of the preceding claims, wherein the solid support is a bead having a mean diameter ranging in size between about 1 μm to about 10 μm or between about 6.5 μm to about 10 μm.

### Claim 13 (depends on 7, 8, 9, 10, 11)

The method of any of claims 7-11, wherein the solid support is a bead having a mean diameter of about 3 μm or about 6.5 μm.

### Claim 14

The method of any of the preceding claims, wherein the fluidic device comprises or consists of a microfluidic chip or sequestration pen.

### Claim 15

The method of any of the preceding claims, wherein a single clone of cells are seeded into the fluidic device.

### Claim 16

The method of any of the preceding claims, wherein the optical signal comprises light emission, optical pattern, or light scattering.

### Claim 17 (depends on 16)

The method of claim 16, wherein the light emission comprises fluorescence emission.

### Claim 18

The method of any of the preceding claims, wherein the change in optical signal is detected using an emission filter.

### Claim 19

The method of any of the preceding claims, wherein the change in optical signal is detected using fluorescence scan.

### Claim 20 (depends on 19)

The method of claim 19, wherein the solid support has an average of 6.5-10 μm, such as about 6.5 μm.

### Claim 21

A system comprising:
a fluidic device;
nanoparticles coated with a ligand for an antibody protein product; and
solid supports coated with a ligand for the antibody protein product,
optionally wherein a mean diameter of the solid supports is greater than that of the nanoparticles.
